Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.31+1.28 (+12.76%)
Close on Nov 17, 2026Market cap $224.25MP/E –Yield –
Keros Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Keros Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $75.86M, down 59.4% year over year. For fiscal 2025 it was $129.64M, down 25.3% from the year before. The highest annual figure on record is $173.63M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.64M | -25.3% |
| FY2024 | Dec 31, 2024 | $173.63M | +28.4% |
| FY2023 | Dec 31, 2023 | $135.26M | +55.0% |
| FY2022 | Dec 31, 2022 | $87.27M | +58.3% |
| FY2021 | Dec 31, 2021 | $55.14M | +62.9% |
| FY2020 | Dec 31, 2020 | $33.86M | +94.8% |
| FY2019 | Dec 31, 2019 | $17.38M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.33M | -48.7% |
| Q1 FY2026 | Mar 31, 2026 | $16.10M | -67.0% |
| Q4 FY2025 | Dec 31, 2025 | $17.91M | -60.7% |
| Q3 FY2025 | Sep 30, 2025 | $19.52M | -60.3% |
| Q2 FY2025 | Jun 30, 2025 | $43.50M | +7.4% |
| Q1 FY2025 | Mar 31, 2025 | $48.71M | +27.3% |
| Q4 FY2024 | Dec 31, 2024 | $45.63M | +21.7% |
| Q3 FY2024 | Sep 30, 2024 | $49.23M | +44.2% |
| Q2 FY2024 | Jun 30, 2024 | $40.52M | +24.5% |
| Q1 FY2024 | Mar 31, 2024 | $38.26M | +23.1% |
| Q4 FY2023 | Dec 31, 2023 | $37.49M | +50.8% |
| Q3 FY2023 | Sep 30, 2023 | $34.14M | +62.3% |
| Q2 FY2023 | Jun 30, 2023 | $32.53M | +39.7% |
| Q1 FY2023 | Mar 31, 2023 | $31.09M | +72.0% |
| Q4 FY2022 | Dec 31, 2022 | $24.87M | +32.0% |
| Q3 FY2022 | Sep 30, 2022 | $21.04M | +41.8% |
| Q2 FY2022 | Jun 30, 2022 | $23.28M | +133.2% |
| Q1 FY2022 | Mar 31, 2022 | $18.08M | +57.3% |
| Q4 FY2021 | Dec 31, 2021 | $18.83M | +94.7% |
| Q3 FY2021 | Sep 30, 2021 | $14.83M | +76.7% |
| Q2 FY2021 | Jun 30, 2021 | $9.98M | +37.4% |
| Q1 FY2021 | Mar 31, 2021 | $11.50M | +34.8% |
| Q4 FY2020 | Dec 31, 2020 | $9.67M | +132.5% |
| Q3 FY2020 | Sep 30, 2020 | $8.40M | +117.8% |
| Q2 FY2020 | Jun 30, 2020 | $7.26M | +61.5% |
| Q1 FY2020 | Mar 31, 2020 | $8.53M | +75.2% |
| Q4 FY2019 | Dec 31, 2019 | $4.16M | – |
| Q3 FY2019 | Sep 30, 2019 | $3.85M | – |
| Q2 FY2019 | Jun 30, 2019 | $4.50M | – |
| Q1 FY2019 | Mar 31, 2019 | $4.87M | – |
See a number that looks wrong?